Abstract:We showed the development of a novel pyrrolopyrimidine derivative as an anti‐glioma agent via potent inhibition of EGFR‐TK. The results suggest that the most potent EGFR‐TK inhibitor, compound 4i, significantly inhibited the proliferation of both wild‐type and mutant glioblastoma cells. It also promoted apoptosis of glioblastoma cells by cell cycle arrest at the G2 phase, possibly via attenuating EGFR‐TK. Glioma is an aggressive type of brain malignancy responsible for significant morbidity and mortality. In the current scenario, epidermal growth factor receptor (EGFR) kinases targeted therapy showed significant benefits in glioma patients. Therefore, in the present study, we intend to investigate the anti‐glioma potential of a novel class of pyrazole‐pyrrolopyrimidine derivatives and their mechanism of action. The compounds will be synthesized in a straight‐forward synthetic route in excellent yields and subsequently tested for EGFR kinase inhibition. The compounds showed a diverse range of inhibitory activity against EGFR (IC50 = 3.4–873.2 nM). With an IC50 of 1.5 nM, compound 4i was determined to be the most effective EGFR inhibitor, even superior to the standard erlotinib (IC50 2.3 nM). Among them, the three most potent compounds (4i, 4j, and 4k) were further subjected to the anticancer activity against the panel of various cancer cell lines MCF‐7 (breast cancer), A549 (lung cancer), U87 (glioblastoma cell)‐EGFR‐Wild Type, U87 (mutant glioblastoma cells) EGFR‐mutant cell, MCF‐12A (normal cells). The compound 4i showed the most potent activity against glioblastoma cells as compared to other cancer cells. The effect of compound 4i was also studied on the apoptosis of U87 cells, where it showed induction of apoptosis in a concentration‐dependent manner. It also showed inhibition of the G2/M cell cycle phase of U87 cells. Our study demonstrated the development of novel pyrazole‐pyrrolopyrimidine derivatives as a novel class of anti‐glioma agents.

Discovery of Novel N -(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma

Identification of Imidazo[4,5-C]pyridin-2-one Derivatives As Novel Src Family Kinase Inhibitors Against Glioblastoma.

N-2-(phenylamino) Benzamide Derivatives As Novel Anti-Glioblastoma Agents: Synthesis and Biological Evaluation.

Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme

Discovery of N-alkyl-N-benzyl thiazoles as novel TRPC antagonists for the treatment of glioblastoma multiforme

Discovery and Optimization of N-Arylated Tetracyclic Dicarboximides That Target Primary Glioma Stem-like Cells

Discovery of N -Trifluoromethylated Noscapines as Novel and Potent Agents for the Treatment of Glioblastoma

Discovery of Novel Analogs of KHS101 As Transforming Acidic Coiled Coil Containing Protein 3 (TACC3) Inhibitors for the Treatment of Glioblastoma

Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent

Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells

Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway Against Glioblastoma.

Novel Piperazine Based Benzamide Derivatives As Potential Anti-Glioblastoma Agents Inhibiting Cell Proliferation and Cell Cycle Progression

Design and discovery of novel pyrazole‐pyrrolopyrimidine derivatives as anti‐glioma agents via promoting apoptosis, inhibiting cell cycle and EGFR‐TK

Design, Synthesis and Biological Evaluation of N-anthraniloyl Tryptamine Derivatives As Pleiotropic Molecules for the Therapy of Malignant Glioma.

Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives As Potent and Selective FGFR Kinase Inhibitors.

Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme

Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1.

Discovery, Design and Synthesis of 6H-Anthra[1,9-cd]isoxazol-6-one Scaffold As G9a Inhibitor Through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification

Discovery of novel ID2 antagonists from pharmacophore-based virtual screening as potential therapeutics for glioma

Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation